Top Page
Day One Biopharmaceuticals
(NASDAQ:DAWN)
Day One Biopharmaceuticals (DAWN) vs. SPDR S&P 500 ETF (SPY)
Day One Biopharmaceuticals Business Overview & Revenue Model
Day One Biopharmaceuticals Earnings Call Summary
Day One Biopharmaceuticals Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 158.18M | 131.16M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 140.97M | 125.88M | -383.00K | -531.00K | -199.00K |
| EBITDA | -105.82M | -86.32M | -188.53M | -141.65M | -72.56M |
| Net Income | -107.32M | -95.50M | -188.92M | -142.18M | -70.64M |
Balance Sheet | |||||
| Total Assets | 507.83M | 582.79M | 376.05M | 349.06M | 289.82M |
| Cash, Cash Equivalents and Short-Term Investments | 441.11M | 531.72M | 366.35M | 342.27M | 284.31M |
| Total Debt | 2.79M | 2.60M | 408.00K | 813.00K | 220.00K |
| Total Liabilities | 66.67M | 80.04M | 29.51M | 17.02M | 8.67M |
| Stockholders Equity | 441.16M | 502.75M | 346.54M | 332.04M | 281.15M |
Cash Flow | |||||
| Free Cash Flow | -104.08M | -80.28M | -150.08M | -109.90M | -56.54M |
| Operating Cash Flow | -103.76M | -78.11M | -146.85M | -109.87M | -48.54M |
| Investing Cash Flow | 174.65M | -230.99M | 128.38M | -255.07M | -8.00M |
| Financing Cash Flow | 1.22M | 203.29M | 164.00M | 165.90M | 297.12M |
Day One Biopharmaceuticals Technical Analysis
Day One Biopharmaceuticals Risk Analysis
Day One Biopharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $705.36M | 51.01 | 14.69% | ― | 27.12% | ― | |
61 Neutral | $2.20B | -8.98 | -23.43% | ― | 31.11% | -46.75% | |
59 Neutral | $1.13B | -25.24 | -14.83% | ― | 2147.20% | -269.99% | |
53 Neutral | $802.05M | -3.61 | -51.07% | ― | -30.56% | 48.79% | |
52 Neutral | $757.87M | -3.27 | -102.59% | ― | ― | -5.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | $109.20M | -4.16 | 242.63% | ― | -58.17% | -116.24% |
Day One Biopharmaceuticals Corporate Events
On March 6, 2026, Servier Pharmaceuticals LLC and Day One Biopharmaceuticals entered into a definitive merger agreement under which Servier will acquire all outstanding Day One shares for $21.50 in cash per share, valuing the company at approximately $2.5 billion. The all-cash tender offer, representing a premium of about 68% to Day One’s prior close and 86% to its one-month VWAP, is not subject to a financing condition and will be followed by a second-step merger once customary conditions, including majority tender and U.S. antitrust clearance, are met.
Day One’s board has unanimously deemed the transaction fair, recommended that shareholders tender their shares and agreed to customary non-solicitation and termination provisions, including an $87.7 million break fee under certain circumstances. For Servier, the deal is intended to strengthen its rare oncology franchise and targeted therapy pipeline, particularly in pediatric low-grade glioma, while giving Day One investors a substantial premium and positioning the combined group as a more prominent player in pediatric and rare oncology markets.
The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On March 2, 2026, Day One Biopharmaceuticals updated its corporate presentation after Ipsen Pharma SAS received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending conditional marketing authorization of OJEMDA as a monotherapy for children with relapsed or refractory BRAF-altered pediatric low-grade glioma. The move underscores Day One’s strategy to build OJEMDA into a global standard of care in pediatric low-grade glioma through its exclusive ex-U.S. licensing deal with Ipsen, while advancing a broader oncology pipeline and signaling a path to sustained revenue growth and strengthened positioning in pediatric oncology therapeutics.
The CHMP’s favorable stance, following Day One’s April 2024 U.S. approval and July 2024 licensing agreement with Ipsen, highlights growing regulatory momentum for OJEMDA in a setting where few approved options exist. For stakeholders, the development points to expanding international commercialization opportunities, reinforces the value of Day One’s pediatric-focused model, and supports the company’s narrative of accelerating growth anchored by OJEMDA and its adjacent oncology programs.
The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Day One Biopharmaceuticals reported on Feb. 24, 2026 that 2025 was a transformational year, driven by strong commercial uptake of its pediatric cancer drug OJEMDA and a broadened oncology pipeline following the January 2026 acquisition of Mersana Therapeutics. OJEMDA generated net product revenue of $52.8 million in the fourth quarter and $155.4 million for full year 2025, representing 172% year-over-year growth and sharp gains in prescription volumes, while the company reaffirmed its 2026 U.S. revenue guidance of $225 million to $250 million.
Clinically, updated three-year FIREFLY-1 data presented in November 2025 underscored the durability and safety of OJEMDA in relapsed or refractory pLGG, and enrollment in the pivotal frontline FIREFLY-2 Phase 3 trial is expected to complete in the first half of 2026. Financially, Day One narrowed its 2025 net loss to $107.3 million on reduced R&D spending and ended the year with $441.1 million in cash and investments, positioning it to advance Phase 1 programs for Emi-Le and DAY301 while maintaining an active presence at upcoming healthcare investor conferences.
The company’s strengthened balance sheet, accelerating OJEMDA franchise, and expanded ADC portfolio underscore its bid to cement a leading position in targeted therapies for rare and pediatric cancers. Stakeholders will closely watch 2026 clinical readouts for Emi-Le and DAY301, alongside completion of FIREFLY-2 enrollment, as key catalysts for Day One’s medium-term growth trajectory.
The most recent analyst rating on (DAWN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On January 11, 2026, Day One Biopharmaceuticals reported preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year, with fourth-quarter sales of about $52.8 million driven by rising patient demand and 1,394 prescriptions in the quarter. The company issued 2026 U.S. net product revenue guidance for OJEMDA of $225 million to $250 million, implying roughly 53% growth at the midpoint, and highlighted a cash, cash equivalents and short-term investment position of about $441.1 million as of December 31, 2025, prior to the Mersana acquisition, underscoring its capacity to fund ongoing commercialization and clinical programs. Management outlined 2026 priorities including expanding OJEMDA’s commercial footprint and solidifying its role as standard of care in second-line pediatric low-grade glioma, completing enrollment in the pivotal Phase 3 FIREFLY-2 trial in first-line pLGG in the first half of 2026, and delivering Phase 1 data for Emi-Le by mid-2026 and initial Phase 1a data for DAY301 in the second half of 2026, positioning the company for further growth and potentially broader oncology indications.
The most recent analyst rating on (DAWN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On January 6, 2026, Day One Biopharmaceuticals completed its acquisition of Mersana Therapeutics in an all-cash tender offer and follow-on merger, paying $25 per share plus a non-tradable contingent value right (CVR) per share that could deliver additional milestone payments of up to $30.25, for potential total consideration of $55.25 per share. The deal, funded with approximately $128.8 million of Day One’s cash on hand, results in Mersana becoming a wholly owned subsidiary and its stock being delisted from Nasdaq, while former Mersana shareholders receive the same mix of cash and CVRs whether they tendered in the offer or were converted in the merger. Each CVR entitles holders to a series of potential cash milestone payments tied to U.S. regulatory designations, clinical trial progress, FDA approval, commercial launches in major global markets, and specified annual net sales thresholds for Emi-Le, with deadlines running from 2026 through 2037, though these milestones are not guaranteed and the CVRs are generally non-transferable. Strategically, the transaction expands Day One’s oncology portfolio with a second clinical-stage antibody-drug conjugate and deepens its push into adult and rare cancers, notably ACC, as the company looks to build on momentum from OJEMDA and position itself as a more diversified player in targeted oncology while assuming the integration and development risks associated with the acquisition and milestone structure.
The most recent analyst rating on (DAWN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.